Table 1 Clinicopathologic characteristics of the patient cohort (n=55)
From: Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
Characteristics | Number (% or range) |
|---|---|
Age at enrolment (median; n=55) | 68 (53–84) years |
Median baseline blood levels | |
PSA (n=55) | 163 ng ml−1 (0.6–3571) |
Haemoglobin (n=55) | 127 g l−1 (84–162) |
ALP (n=45) | 125 U l−1 (36–2962) |
Metastatic site ( n =55) | |
None | 4 (7%) |
Bone only | 30 (55%) |
Visceral/soft tissue | 8 (15%) |
Bone and visceral | 13 (23%) |
Gleason score at diagnosis ( n =44) | |
6 | 4 (9%) |
7 | 16 (36%) |
8 | 7 (16%) |
9 | 15 (34%) |
10 | 2 (5%) |
PSA response to treatment ( n =55) | |
PR | 35 (64%) |
SD | 14 (25%) |
PD | 6 (11%) |
Subsequent systemic therapy | |
Mitoxantrone | 4 (7%) |
Abiraterone | 3 (5%) |
